Lisata Therapeutics, Inc.
LSTA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.00
KIRA · Stoqly’s AI analyst, in plain words
- Lisata Therapeutics, Inc. had $0.2M of revenue in fiscal 2024, down 83.0% on the year before.
- Its operating margin was −10,711.2%, down 8,470.3 pts: of every 100 in sales, about −10,711 is left after running the business.
- Lisata Therapeutics, Inc. lost $16.6M in fiscal 2024.
- Free cash flow was −$16.0M in fiscal 2024, −9,398.2% of revenue.
Market cap
$9.1M
P/E
—
Revenue
$0.2M
Net income
−$16.6M
Free cash flow
−$16.0M
Operating margin
−10,711.2%
Lisata Therapeutics, Inc. in 30 seconds · fiscal 2024
Are sales growing?
−83.0%
No. Sales fell 83.0% last year.
Does it make a profit?
−9,756.5%
No. It lost money last year.
Does profit turn into cash?
−9,398.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lisata Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- LISATA THERAPEUTICS, INC.
- CIK
- 0000320017
Lisata Therapeutics, Inc. · LSTA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.0M | $1.0M | $0.2M |
| Revenue growth | — | — | — | — | −83.0% |
| Operating margin | — | — | — | −2,240.9% | −10,711.2% |
| Net income | −$27.5M | −$54.2M | −$20.8M | −$20.0M | −$16.6M |
| Net margin | — | — | — | −1,998.5% | −9,756.5% |
| Diluted EPS | −$7.45 | −$10.47 | −$2.58 | −$2.40 | −$1.91 |
| Cash | |||||
| Cash from operations | −$22.2M | −$21.2M | −$20.0M | −$19.4M | −$15.9M |
| Capital expenditure | $0.1M | $0.3M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$22.3M | −$21.5M | −$20.0M | −$19.4M | −$16.0M |
| FCF margin | — | — | — | −1,935.6% | −9,398.2% |
| Share count change | −76.1% | 40.5% | 55.8% | 3.2% | 4.3% |
| Debt and strength | |||||
| Cash and short-term investments | $24.6M | $32.2M | $22.6M | $16.2M | $16.0M |
| Shareholders' equity | $92.3M | $66.6M | $48.1M | $29.6M | $14.9M |
| Current ratio | 21.3x | 11.3x | 8.2x | 6.2x | 5.8x |
| Returns and quality | |||||
| Return on equity | −44.0% | −68.3% | −36.3% | −51.4% | −74.7% |
| Return on tangible equity | −29.8% | −81.9% | −43.6% | −68.5% | −114.7% |
| Piotroski F-score | — | — | 2 | 2 | 1 |
| Altman Z'' | 8.3 | −11.6 | −21.5 | −44.5 | −100.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lisata Therapeutics, Inc. · LSTA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.00 a share, the company is worth $9.1M.
Source: SEC EDGAR XBRL filings (CIK 0000320017). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.